메뉴 건너뛰기




Volumn 78, Issue 10, 2018, Pages 1037-1048

Empagliflozin: A Review in Type 2 Diabetes

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

EID: 85049064712     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-018-0937-z     Document Type: Review
Times cited : (103)

References (84)
  • 1
    • 84875462788 scopus 로고    scopus 로고
    • Impact of diabetes on cardiovascular disease: an update
    • PID: 23533715
    • Matheus AS, Tannus LR, Cobas RA, et al. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013;2013:653789.
    • (2013) Int J Hypertens. , vol.2013 , pp. 653789
    • Matheus, A.S.1    Tannus, L.R.2    Cobas, R.A.3
  • 2
    • 84919999219 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • PID: 25538310
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.
    • (2015) Diabetes Care , vol.38 , Issue.1 , pp. 140-149
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 3
    • 84901467782 scopus 로고    scopus 로고
    • Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
    • PID: 24920930
    • Lorber D. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2014;7:169–83.
    • (2014) Diabetes Metab Syndr Obes. , vol.7 , pp. 169-183
    • Lorber, D.1
  • 4
    • 84979609753 scopus 로고    scopus 로고
    • Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm
    • PID: 27440828
    • Wilding JPH, Rajeev SP, DeFronzo RA. Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm. Diabetes Care. 2016;39(Suppl 2):S154–64.
    • (2016) Diabetes Care , vol.39 , pp. S154-S164
    • Wilding, J.P.H.1    Rajeev, S.P.2    DeFronzo, R.A.3
  • 5
    • 84964773926 scopus 로고    scopus 로고
    • SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study
    • PID: 27208375
    • Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39:717–25.
    • (2016) Diabetes Care , vol.39 , pp. 717-725
    • Abdul-Ghani, M.1    Del Prato, S.2    Chilton, R.3
  • 7
    • 85019207240 scopus 로고    scopus 로고
    • US prescribing information, Accessed 8 June 2018
    • ® (empagliflozin) tablets, for oral use. US prescribing information. 2016. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf. Accessed 8 June 2018.
    • (2016) ® (Empagliflozin) tablets, for oral use
  • 8
    • 84921937734 scopus 로고    scopus 로고
    • Empagliflozin: a review of its use in patients with type 2 diabetes mellitus
    • PID: 25274537
    • Scott LJ. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(15):1769–84.
    • (2014) Drugs. , vol.74 , Issue.15 , pp. 1769-1784
    • Scott, L.J.1
  • 9
    • 84896826460 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor
    • PID: 24430725
    • Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213–25.
    • (2014) Clin Pharmacokinet , vol.53 , Issue.3 , pp. 213-225
    • Scheen, A.J.1
  • 10
    • 85009081205 scopus 로고    scopus 로고
    • Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials
    • Levine MJ. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev. 2016;12(4):1–19.
    • (2016) Curr Diabetes Rev , vol.12 , Issue.4 , pp. 1-19
    • Levine, M.J.1
  • 11
    • 84930381949 scopus 로고    scopus 로고
    • Empagliflozin for the treatment of type 2 diabetes mellitus: an overview of safety and efficacy based on phase 3 trials
    • PID: 25676662
    • Dailey G. Empagliflozin for the treatment of type 2 diabetes mellitus: an overview of safety and efficacy based on phase 3 trials. J Diabetes. 2015;7(4):448–61.
    • (2015) J Diabetes. , vol.7 , Issue.4 , pp. 448-461
    • Dailey, G.1
  • 12
    • 84885954870 scopus 로고    scopus 로고
    • Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
    • PID: 24622369
    • Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208–19.
    • (2013) Lancet Diabetes Endocrinol. , vol.1 , Issue.3 , pp. 208-219
    • Roden, M.1    Weng, J.2    Eilbracht, J.3
  • 13
    • 84901455931 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial
    • Hӓring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650–9.
    • (2014) Diabetes Care , vol.37 , Issue.6 , pp. 1650-1659
    • Hӓring, H.-U.1    Merker, L.2    Seewaldt-Becker, E.3
  • 14
    • 84885952950 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial
    • Hӓring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36(11):3396–404.
    • (2013) Diabetes Care , vol.36 , Issue.11 , pp. 3396-3404
    • Hӓring, H.-U.1    Merker, L.2    Seewaldt-Becker, E.3
  • 15
    • 84892477577 scopus 로고    scopus 로고
    • Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
    • PID: 23906415
    • Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16(2):147–58.
    • (2014) Diabetes Obes Metab , vol.16 , Issue.2 , pp. 147-158
    • Kovacs, C.S.1    Seshiah, V.2    Swallow, R.3
  • 16
    • 85011649841 scopus 로고    scopus 로고
    • Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial
    • PID: 27913576
    • Søfteland E, Meier JJ, Vangen B, et al. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. Diabetes Care. 2017;40(2):201–9.
    • (2017) Diabetes Care , vol.40 , Issue.2 , pp. 201-209
    • Søfteland, E.1    Meier, J.J.2    Vangen, B.3
  • 17
    • 84908332537 scopus 로고    scopus 로고
    • Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week, randomised, active-controlled, double-blind, phase 3 trial
    • PID: 24948511
    • Ridderstrale M, Andersen RK, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week, randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(3):691–700.
    • (2014) Lancet Diabetes Endocrinol. , vol.2 , Issue.3 , pp. 691-700
    • Ridderstrale, M.1    Andersen, R.K.2    Zeller, C.3
  • 18
    • 84942294658 scopus 로고    scopus 로고
    • Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
    • PID: 26040302
    • Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936–48.
    • (2015) Diabetes Obes Metab , vol.17 , Issue.10 , pp. 936-948
    • Rosenstock, J.1    Jelaska, A.2    Zeller, C.3
  • 19
    • 84899961819 scopus 로고    scopus 로고
    • Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
    • PID: 24795251
    • Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369–84.
    • (2014) Lancet Diabetes Endocrinol. , vol.2 , Issue.5 , pp. 369-384
    • Barnett, A.H.1    Mithal, A.2    Manassie, J.3
  • 20
    • 84928196614 scopus 로고    scopus 로고
    • Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
    • PID: 25271206
    • Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420–8.
    • (2015) Diabetes Care , vol.38 , Issue.3 , pp. 420-428
    • Tikkanen, I.1    Narko, K.2    Zeller, C.3
  • 21
    • 84903511385 scopus 로고    scopus 로고
    • Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycaemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
    • PID: 24929430
    • Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycaemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37:1815–23.
    • (2014) Diabetes Care , vol.37 , pp. 1815-1823
    • Rosenstock, J.1    Jelaska, A.2    Frappin, G.3
  • 22
    • 84952990032 scopus 로고    scopus 로고
    • Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial
    • PID: 26701110
    • Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154.
    • (2015) Cardiovasc Diabetol. , vol.14 , pp. 154
    • Roden, M.1    Merker, L.2    Christiansen, A.V.3
  • 23
    • 84983201802 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin in people with type 2 diabetes
    • PID: 26031566
    • Merker L, Haring HU, Christiansen AV, et al. Empagliflozin as add-on to metformin in people with type 2 diabetes. Diabet Med. 2015;32(12):1555–67.
    • (2015) Diabet Med , vol.32 , Issue.12 , pp. 1555-1567
    • Merker, L.1    Haring, H.U.2    Christiansen, A.V.3
  • 24
    • 84943200890 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
    • PID: 26324220
    • Haering H-U, Merker L, Christiansen AV, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;110(1):82–90.
    • (2015) Diabetes Res Clin Pract , vol.110 , Issue.1 , pp. 82-90
    • Haering, H.-U.1    Merker, L.2    Christiansen, A.V.3
  • 25
    • 84940575211 scopus 로고    scopus 로고
    • Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus
    • Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther. 2015;37(8):1773–88.e1.
    • (2015) Clin Ther , vol.37 , Issue.8 , pp. 1773-1788
    • Kovacs, C.S.1    Seshiah, V.2    Merker, L.3
  • 26
    • 85017311969 scopus 로고    scopus 로고
    • Influence of baseline HbA1c, BMI, beta-cell function, and insulin sensitivity on the treatment response of empagliflozin (EMPA) in patients with type 2 diabetes (T2DM)
    • [abstract no. 118-LB], LB31
    • Ridderstrale M, Elsasser U, Zeller C, et al. Influence of baseline HbA1c, BMI, beta-cell function, and insulin sensitivity on the treatment response of empagliflozin (EMPA) in patients with type 2 diabetes (T2DM) [abstract no. 118-LB]. Diabetes. 2015;64(Suppl 1A):LB31.
    • (2015) Diabetes , vol.64
    • Ridderstrale, M.1    Elsasser, U.2    Zeller, C.3
  • 27
    • 84994409150 scopus 로고    scopus 로고
    • Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus
    • Romera I, Ampudia-Blasco FJ, Perez A, et al. Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. Endocrinologia y Nutricion (English Edition). 2016;63(10):519–26.
    • (2016) Endocrinologia y Nutricion (English Edition). , vol.63 , Issue.10 , pp. 519-526
    • Romera, I.1    Ampudia-Blasco, F.J.2    Perez, A.3
  • 28
    • 85028413629 scopus 로고    scopus 로고
    • Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
    • PID: 28860019
    • Cherney DZI, Cooper ME, Tikkanen I, et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93(1):231–44.
    • (2018) Kidney Int , vol.93 , Issue.1 , pp. 231-244
    • Cherney, D.Z.I.1    Cooper, M.E.2    Tikkanen, I.3
  • 29
    • 84902756416 scopus 로고    scopus 로고
    • Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
    • PID: 24943000
    • Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol. 2014;13:102.
    • (2014) Cardiovasc Diabetol. , vol.13 , pp. 102
    • Zinman, B.1    Inzucchi, S.E.2    Lachin, J.M.3
  • 30
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • PID: 26378978
    • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
    • (2015) N Engl J Med , vol.373 , Issue.22 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 32
    • 84975698839 scopus 로고    scopus 로고
    • Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial
    • PID: 26819227
    • Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016;37(19):1526–34.
    • (2016) Eur Heart J , vol.37 , Issue.19 , pp. 1526-1534
    • Fitchett, D.1    Zinman, B.2    Wanner, C.3
  • 33
    • 84979895487 scopus 로고    scopus 로고
    • Empagliflozin and progression of kidney disease in type 2 diabetes
    • PID: 27299675
    • Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34.
    • (2016) N Engl J Med , vol.375 , Issue.4 , pp. 323-334
    • Wanner, C.1    Inzucchi, S.E.2    Lachin, J.M.3
  • 34
    • 85057148754 scopus 로고    scopus 로고
    • Consistent effect of empagliflozin on composite outcomes related to heart failure: results from EMPA-REG OUTCOME [abstract no. 182]
    • Schnee J, Inzucchi SE, Zinman B, et al. Consistent effect of empagliflozin on composite outcomes related to heart failure: results from EMPA-REG OUTCOME [abstract no. 182]. Diabetologia. 2017;60(Suppl 1):S85–6.
    • (2017) Diabetologia , vol.60 , pp. S85-S86
    • Schnee, J.1    Inzucchi, S.E.2    Zinman, B.3
  • 35
    • 85057144497 scopus 로고    scopus 로고
    • Empagliflozin (EMPA) reduces mortality in analyses adjusted for control of blood pressure (BP), low density lipoprotein cholesterol (LDL-C) and HbA1c over time [abstract no. 42]
    • Fitchett D, Mathieu C, Kaspers S, et al. Empagliflozin (EMPA) reduces mortality in analyses adjusted for control of blood pressure (BP), low density lipoprotein cholesterol (LDL-C) and HbA1c over time [abstract no. 42]. Diabetologia. 2017;60(Suppl 1):S21.
    • (2017) Diabetologia , vol.60 , pp. S21
    • Fitchett, D.1    Mathieu, C.2    Kaspers, S.3
  • 36
    • 85057180208 scopus 로고    scopus 로고
    • Empagliflozin (EMPA) reduces heart failure outcomes irrespective of blood pressure (BP), low density lipoprotein cholesterol (LDL-C) and HbA1c control [abstract no. 899]
    • McKnight J, Fitchett D, Lee J, et al. Empagliflozin (EMPA) reduces heart failure outcomes irrespective of blood pressure (BP), low density lipoprotein cholesterol (LDL-C) and HbA1c control [abstract no. 899]. Diabetologia. 2017;60(1 Suppl 1):S416–7.
    • (2017) Diabetologia , vol.60 , Issue.1 , pp. S416-S417
    • McKnight, J.1    Fitchett, D.2    Lee, J.3
  • 37
    • 85042792101 scopus 로고    scopus 로고
    • Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease
    • PID: 28904068
    • Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease. Circulation. 2018;137(2):119–29.
    • (2018) Circulation , vol.137 , Issue.2 , pp. 119-129
    • Wanner, C.1    Lachin, J.M.2    Inzucchi, S.E.3
  • 38
    • 85010749154 scopus 로고    scopus 로고
    • Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease - results from EMPA-REG OUTCOME
    • PID: 28025462
    • Kaku K, Lee J, Mattheus M, et al. Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease - results from EMPA-REG OUTCOME. Circ J. 2017;81(2):227–34.
    • (2017) Circ J , vol.81 , Issue.2 , pp. 227-234
    • Kaku, K.1    Lee, J.2    Mattheus, M.3
  • 39
    • 85034212680 scopus 로고    scopus 로고
    • Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME
    • PID: 29133602
    • Verma S, Mazer CD, Al-Omran M, et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation. 2017;137(4):405–7.
    • (2017) Circulation. , vol.137 , Issue.4 , pp. 405-407
    • Verma, S.1    Mazer, C.D.2    Al-Omran, M.3
  • 40
    • 84983422189 scopus 로고    scopus 로고
    • Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials
    • PID: 27376831
    • Salsali A, Kim G, Woerle HJ, et al. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. Diabetes Obes Metab. 2016;18(10):1034–40.
    • (2016) Diabetes Obes Metab , vol.18 , Issue.10 , pp. 1034-1040
    • Salsali, A.1    Kim, G.2    Woerle, H.J.3
  • 41
    • 85020107839 scopus 로고    scopus 로고
    • EMPA-REG OUTCOME: the nephrologist’s point of view
    • PID: 28526179
    • Wanner C. EMPA-REG OUTCOME: the nephrologist’s point of view. Am J Med. 2017;130(Suppl 6):S63–72.
    • (2017) Am J Med , vol.130 , pp. S63-S72
    • Wanner, C.1
  • 42
    • 84994180780 scopus 로고    scopus 로고
    • Empagliflozin and progression of kidney disease in type 2 diabetes
    • PID: 27806236
    • Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(18):1801–2.
    • (2016) N Engl J Med , vol.375 , Issue.18 , pp. 1801-1802
    • Wanner, C.1    Inzucchi, S.E.2    Zinman, B.3
  • 43
    • 85021054097 scopus 로고    scopus 로고
    • Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I–III clinical trials
    • PID: 28631216
    • Kohler S, Zeller C, Iliev H, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I–III clinical trials. Adv Ther. 2017;34(7):1707–26.
    • (2017) Adv Ther. , vol.34 , Issue.7 , pp. 1707-1726
    • Kohler, S.1    Zeller, C.2    Iliev, H.3
  • 44
    • 85057155208 scopus 로고    scopus 로고
    • Safety and tolerability of empagliflozin in patients with t2d and advanced kidney disease: a large, pooled analysis of placebo-controlled clinical trials (abstract no. 1218-P plus poster)
    • Levin A, Nangaku M, Kadowaki T, et al. Safety and tolerability of empagliflozin in patients with t2d and advanced kidney disease: a large, pooled analysis of placebo-controlled clinical trials (abstract no. 1218-P plus poster). Diabetes. 2017;66(Suppl 1):A325.
    • (2017) Diabetes , vol.66 , pp. A325
    • Levin, A.1    Nangaku, M.2    Kadowaki, T.3
  • 45
    • 85029504121 scopus 로고    scopus 로고
    • Effect of empagliflozin (EMPA) on diabetic ketoacidosis (DKA) in patients with type 2 diabetes (T2DM): pooled clinical trial data [abstract no. 50]
    • Lund S, Solimando F, Kohler S, et al. Effect of empagliflozin (EMPA) on diabetic ketoacidosis (DKA) in patients with type 2 diabetes (T2DM): pooled clinical trial data [abstract no. 50]. Diabetologia. 2016;59(Suppl 1):S26–7.
    • (2016) Diabetologia , vol.59 , pp. S26-S27
    • Lund, S.1    Solimando, F.2    Kohler, S.3
  • 46
    • 85016021198 scopus 로고    scopus 로고
    • Sodium–glucose cotransporter 2 inhibition: cardioprotection by treating diabetes—a translational viewpoint explaining its potential salutary effects
    • PID: 27533948
    • de Leeuw AE, de Boer R. Sodium–glucose cotransporter 2 inhibition: cardioprotection by treating diabetes—a translational viewpoint explaining its potential salutary effects. Eur Heart J Cardiovasc Pharmacother. 2016;2:244–55.
    • (2016) Eur Heart J Cardiovasc Pharmacother. , vol.2 , pp. 244-255
    • de Leeuw, A.E.1    de Boer, R.2
  • 47
    • 85041180129 scopus 로고    scopus 로고
    • How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial
    • PID: 29203583
    • Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(2):356–63.
    • (2018) Diabetes Care , vol.41 , Issue.2 , pp. 356-363
    • Inzucchi, S.E.1    Zinman, B.2    Fitchett, D.3
  • 48
    • 85018499284 scopus 로고    scopus 로고
    • Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
    • PID: 28403850
    • Tanaka A, Shimabukuro M, Okada Y, et al. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol. 2017;16(1):48.
    • (2017) Cardiovasc Diabetol. , vol.16 , Issue.1 , pp. 48
    • Tanaka, A.1    Shimabukuro, M.2    Okada, Y.3
  • 49
    • 85038951494 scopus 로고    scopus 로고
    • Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors’ Expert Forum
    • PID: 29263194
    • Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care. 2018;41(1):14–31.
    • (2018) Diabetes Care , vol.41 , Issue.1 , pp. 14-31
    • Cefalu, W.T.1    Kaul, S.2    Gerstein, H.C.3
  • 51
    • 85040076345 scopus 로고    scopus 로고
    • Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: established and emerging agents
    • PID: 29305768
    • Saxon DR, Rasouli N, Eckel RH. Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: established and emerging agents. Drugs. 2018;78(2):203–14.
    • (2018) Drugs. , vol.78 , Issue.2 , pp. 203-214
    • Saxon, D.R.1    Rasouli, N.2    Eckel, R.H.3
  • 52
    • 85019731757 scopus 로고    scopus 로고
    • Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study
    • PID: 28522450
    • Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation. 2017;136(3):249–59.
    • (2017) Circulation , vol.136 , Issue.3 , pp. 249-259
    • Kosiborod, M.1    Cavender, M.A.2    Fu, A.Z.3
  • 53
    • 85047499725 scopus 로고    scopus 로고
    • Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
    • PID: 29540325
    • Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628–39.
    • (2018) J Am Coll Cardiol , vol.71 , Issue.23 , pp. 2628-2639
    • Kosiborod, M.1    Lam, C.S.P.2    Kohsaka, S.3
  • 54
    • 84960433486 scopus 로고    scopus 로고
    • SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
    • PID: 26911584
    • Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6(2):e009417.
    • (2016) BMJ Open , vol.6 , Issue.2
    • Shyangdan, D.S.1    Uthman, O.A.2    Waugh, N.3
  • 55
    • 84969915634 scopus 로고    scopus 로고
    • Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
    • PID: 27059700
    • Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783–94.
    • (2016) Diabetes Obes Metab , vol.18 , Issue.8 , pp. 783-794
    • Zaccardi, F.1    Webb, D.R.2    Htike, Z.Z.3
  • 56
    • 85045087552 scopus 로고    scopus 로고
    • Does lower limb amputation concern all SGLT2 inhibitors?
    • PID: 29626204
    • Scheen AJ. Does lower limb amputation concern all SGLT2 inhibitors? Nat Rev Endocrinol. 2018;14(6):326–8.
    • (2018) Nat Rev Endocrinol. , vol.14 , Issue.6 , pp. 326-328
    • Scheen, A.J.1
  • 57
    • 85038950538 scopus 로고    scopus 로고
    • Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial
    • PID: 29133344
    • Inzucchi SE, Iliev H, Pfarr E, et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(1):e4–5.
    • (2018) Diabetes Care , vol.41 , Issue.1 , pp. e4-e5
    • Inzucchi, S.E.1    Iliev, H.2    Pfarr, E.3
  • 58
    • 85040177178 scopus 로고    scopus 로고
    • Initiation of dapagliflozin and treatment-emergent fractures
    • PID: 29193543
    • Toulis KA, Bilezikian JP, Thomas GN, et al. Initiation of dapagliflozin and treatment-emergent fractures. Diabetes Obes Metab. 2018;20(4):1070–4.
    • (2018) Diabetes Obes Metab , vol.20 , Issue.4 , pp. 1070-1074
    • Toulis, K.A.1    Bilezikian, J.P.2    Thomas, G.N.3
  • 59
    • 85020403719 scopus 로고    scopus 로고
    • Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
    • PID: 28591538
    • Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376:2300–2.
    • (2017) N Engl J Med , vol.376 , pp. 2300-2302
    • Fralick, M.1    Schneeweiss, S.2    Patorno, E.3
  • 60
    • 84980337086 scopus 로고    scopus 로고
    • Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials
    • PID: 27311492
    • Tang H, Li D, Wang T, et al. Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2016;39(8):e123–4.
    • (2016) Diabetes Care , vol.39 , Issue.8 , pp. e123-e124
    • Tang, H.1    Li, D.2    Wang, T.3
  • 61
    • 84962439093 scopus 로고    scopus 로고
    • Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors
    • PID: 26294774
    • Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638–42.
    • (2015) Diabetes Care , vol.38 , pp. 1638-1642
    • Rosenstock, J.1    Ferrannini, E.2
  • 62
    • 85039705599 scopus 로고    scopus 로고
    • Pharmacological approaches to glycemic treatment. Sect. 8
    • American Diabetes Association. Pharmacological approaches to glycemic treatment. Sect. 8. In: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73–85.
    • (2018) Standards of Medical Care in Diabetes-2018. Diabetes Care , vol.41 , pp. S73-S85
  • 63
    • 85044526898 scopus 로고    scopus 로고
    • Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary
    • PID: 29368965
    • Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary. Endocr Pract. 2018;24(1):91–120.
    • (2018) Endocr Pract. , vol.24 , Issue.1 , pp. 91-120
    • Garber, A.J.1    Abrahamson, M.J.2    Barzilay, J.I.3
  • 64
    • 84876062008 scopus 로고    scopus 로고
    • Pharmacologic management of type 2 diabetes
    • Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes. Can J Diabetes. 2013;37(Suppl 1):S61–8.
    • (2013) Can J Diabetes. , vol.37 , pp. S61-S68
  • 65
    • 84979513591 scopus 로고    scopus 로고
    • Clinical considerations for use of initial combination therapy in type 2 diabetes
    • PID: 27440826
    • Cahn A, Cefalu WT. Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care. 2016;39(Suppl 2):S137–45.
    • (2016) Diabetes Care , vol.39 , pp. S137-S145
    • Cahn, A.1    Cefalu, W.T.2
  • 66
    • 85049291264 scopus 로고    scopus 로고
    • November, interim update, Accessed 8 June 2018
    • Diabetes Canada. Pharmacologic management of type 2 diabetes: November 2016 interim update. http://guidelines.diabetes.ca. Accessed 8 June 2018.
    • (2016) Pharmacologic Management of Type 2 Diabetes
  • 67
    • 84980396108 scopus 로고    scopus 로고
    • 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
    • PID: 27206819
    • Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129–200.
    • (2016) Eur Heart J , vol.37 , Issue.27 , pp. 2129-2200
    • Ponikowski, P.1    Voors, A.A.2    Anker, S.D.3
  • 68
    • 85046057841 scopus 로고    scopus 로고
    • Cost effectiveness of empagliflozin in patients with T2DM and high CV risk in Canada [abstract no. PDB52]
    • Mettam SR, Bajaj H, Kansal AR, et al. Cost effectiveness of empagliflozin in patients with T2DM and high CV risk in Canada [abstract no. PDB52]. Value Health. 2016;19(7):A674.
    • (2016) Value Health. , vol.19 , Issue.7 , pp. A674
    • Mettam, S.R.1    Bajaj, H.2    Kansal, A.R.3
  • 69
    • 85039931669 scopus 로고    scopus 로고
    • Cost-effectiveness of empagliflozin (jardiance) in the treatment of patients with type 2 diabetes mellitus (T2DM) in the UK based on EMPA-REG outcome data [abstract no. PDB46]
    • Daacke I, Kandaswamy P, Tebboth A, et al. Cost-effectiveness of empagliflozin (jardiance) in the treatment of patients with type 2 diabetes mellitus (T2DM) in the UK based on EMPA-REG outcome data [abstract no. PDB46]. Value Health. 2016;19(7):A673.
    • (2016) Value Health. , vol.19 , Issue.7 , pp. A673
    • Daacke, I.1    Kandaswamy, P.2    Tebboth, A.3
  • 71
    • 84878947970 scopus 로고    scopus 로고
    • Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes
    • PID: 23356556
    • Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613–21.
    • (2013) Diabetes Obes Metab , vol.15 , Issue.7 , pp. 613-621
    • Heise, T.1    Seewaldt-Becker, E.2    Macha, S.3
  • 72
    • 84893872877 scopus 로고    scopus 로고
    • Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
    • PID: 24463454
    • Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508.
    • (2014) J Clin Invest. , vol.124 , Issue.2 , pp. 499-508
    • Ferrannini, E.1    Muscelli, E.2    Frascerra, S.3
  • 73
    • 85045436396 scopus 로고    scopus 로고
    • Empagliflozin treatment is associated with improved beta cell function in T2DM
    • PID: 29342295
    • Al Jobori H, Daniele G, Adams J, et al. Empagliflozin treatment is associated with improved beta cell function in T2DM. J Clin Endocrinol Metab. 2018;103(4):1402–7.
    • (2018) J Clin Endocrinol Metab , vol.103 , Issue.4 , pp. 1402-1407
    • Al Jobori, H.1    Daniele, G.2    Adams, J.3
  • 74
    • 84911476493 scopus 로고    scopus 로고
    • Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes
    • PID: 24964723
    • Riggs MM, Seman LJ, Staab A, et al. Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes. Br J Clin Pharmacol. 2014;78(6):1407–18.
    • (2014) Br J Clin Pharmacol , vol.78 , Issue.6 , pp. 1407-1418
    • Riggs, M.M.1    Seman, L.J.2    Staab, A.3
  • 75
    • 84945455839 scopus 로고    scopus 로고
    • Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
    • PID: 26343814
    • Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180–93.
    • (2015) Diabetes Obes Metab , vol.17 , Issue.12 , pp. 1180-1193
    • Chilton, R.1    Tikkanen, I.2    Cannon, C.P.3
  • 76
    • 85057177080 scopus 로고    scopus 로고
    • Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex, and hypertension in patients with T2DM and high CV Risk: EMPA-REG OUTCOME [abstract no. 452-P and poster]
    • Chilton RJ, Gullestad L, Fitchett D, et al. Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex, and hypertension in patients with T2DM and high CV Risk: EMPA-REG OUTCOME [abstract no. 452-P and poster]. Diabetes. 2017;66(Suppl 1):A119.
    • (2017) Diabetes , vol.66 , pp. A119
    • Chilton, R.J.1    Gullestad, L.2    Fitchett, D.3
  • 77
    • 84958158486 scopus 로고    scopus 로고
    • Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
    • PID: 26873905
    • Neeland IJ, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13(2):119–26.
    • (2016) Diab Vasc Dis Res. , vol.13 , Issue.2 , pp. 119-126
    • Neeland, I.J.1    McGuire, D.K.2    Chilton, R.3
  • 78
    • 85057192553 scopus 로고    scopus 로고
    • Effect of empagliflozin on anthropometry and indices of visceral and total adiposity in patients with type 2 diabetes and high cardiovascular risk: EMPA-REG OUTCOME [abstract no. 730]
    • Neeland IJ, McGuire DK, Fernandez CS, et al. Effect of empagliflozin on anthropometry and indices of visceral and total adiposity in patients with type 2 diabetes and high cardiovascular risk: EMPA-REG OUTCOME [abstract no. 730]. Diabetologia. 2016;59(Suppl 1):S348.
    • (2016) Diabetologia , vol.59 , pp. S348
    • Neeland, I.J.1    McGuire, D.K.2    Fernandez, C.S.3
  • 79
    • 84975153660 scopus 로고    scopus 로고
    • The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
    • PID: 27316632
    • Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59(9):1860–70.
    • (2016) Diabetologia , vol.59 , Issue.9 , pp. 1860-1870
    • Cherney, D.1    Lund, S.S.2    Perkins, B.A.3
  • 80
    • 85021254729 scopus 로고    scopus 로고
    • Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
    • PID: 28666775
    • Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):610–21.
    • (2017) Lancet Diabetes Endocrinol. , vol.5 , Issue.8 , pp. 610-621
    • Cherney, D.Z.I.1    Zinman, B.2    Inzucchi, S.E.3
  • 81
    • 85020043362 scopus 로고    scopus 로고
    • EMPA-REG OUTCOME: the cardiologist’s point of view
    • PID: 28526181
    • Pham SV, Chilton R. EMPA-REG OUTCOME: the cardiologist’s point of view. Am J Med. 2017;130:S57–62.
    • (2017) Am J Med , vol.130 , pp. S57-S62
    • Pham, S.V.1    Chilton, R.2
  • 82
    • 84951814585 scopus 로고    scopus 로고
    • The EMPA-REG study: what has it told us? A diabetologist’s perspective
    • PID: 26541076
    • Defronzo RA. The EMPA-REG study: what has it told us? A diabetologist’s perspective. J Diabetes Complicat. 2016;30(1):1–2.
    • (2016) J Diabetes Complicat. , vol.30 , Issue.1 , pp. 1-2
    • Defronzo, R.A.1
  • 83
    • 84936947049 scopus 로고    scopus 로고
    • Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers
    • PID: 25547626
    • Chen LZ, Jungnik A, Mao Y, et al. Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers. Xenobiotica. 2015;45(6):520–9.
    • (2015) Xenobiotica , vol.45 , Issue.6 , pp. 520-529
    • Chen, L.Z.1    Jungnik, A.2    Mao, Y.3
  • 84
    • 84923791994 scopus 로고    scopus 로고
    • Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
    • PID: 25488697
    • Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59.
    • (2015) Drugs. , vol.75 , Issue.1 , pp. 33-59
    • Scheen, A.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.